Salarius Pharmaceuticals, Inc. Share Price
Equities
SLRX
US79400X3052
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5059 USD | -5.66% | +1.38% | -22.17% |
03-25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
03-25 | Top Premarket Gainers | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.31M 185M |
---|---|---|---|---|---|
Net income 2024 * | -21M -1.68B | Net income 2025 * | -23M -1.84B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.02
x | P/E ratio 2025 * |
-0.02
x | Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.92% |
1 day | -4.90% | ||
1 week | +1.38% | ||
Current month | +1.38% | ||
1 month | +11.88% | ||
3 months | -7.17% | ||
6 months | -34.30% | ||
Current year | -22.17% |
Managers | Title | Age | Since |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 18/07/19 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 09/09/19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 18/07/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 18/07/19 |
Paul Lammers
BRD | Director/Board Member | 66 | 18/07/19 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 18/06/20 |
Date | Price | Change | Volume |
---|---|---|---|
02/05/24 | 0.5059 | -5.66% | 58 407 |
01/05/24 | 0.5363 | +7.47% | 39,567 |
30/04/24 | 0.499 | +3.10% | 9,974 |
29/04/24 | 0.484 | -2.24% | 12,234 |
26/04/24 | 0.4951 | -0.78% | 4,071 |
Delayed Quote Nasdaq, May 02, 2024 at 04:38 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.17% | 2.31M | |
+19.26% | 42.68B | |
-3.25% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.28% | 24.94B | |
-20.17% | 18.96B | |
+30.21% | 12.3B | |
-2.61% | 11.95B | |
-2.73% | 11.55B |
- Stock Market
- Equities
- SLRX Stock